Cargando…

Functional analysis and clinical significance of the isocitrate dehydrogenase 2 gene in papillary thyroid carcinoma

Objective: Mitochondrial NADP+-dependent isocitrate dehydrogenase 2 (IDH2) is a major producer of mitochondrial NADPH. IDH2-related research has focused on its mutation mechanism and its clinical significance, but the role of wild-type IDH2 in carcinoma remains controversial. Altered IDH2 levels hav...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Jun, Hu, Linfei, Wang, Huijuan, Zhi, Jingtai, Hou, Xiukun, Wu, Yu, Zheng, Xiangqian, Gao, Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503344/ https://www.ncbi.nlm.nih.gov/pubmed/31118795 http://dx.doi.org/10.2147/CMAR.S194920

Ejemplares similares

BRMS1 downregulation is a poor prognostic biomarker in anaplastic thyroid carcinoma patients
por: Wu, Yu, et al.
Publicado: (2019)

Correlation between obesity and clinicopathological characteristics in patients with papillary thyroid cancer: a study of 1579 cases: a retrospective study
por: Wang, Huijuan, et al.
Publicado: (2020)

Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib
por: Hu, Linfei, et al.
Publicado: (2022)

The mechanisms of celastrol in treating papillary thyroid carcinoma based on network pharmacology and experiment verification
por: Yi, Jiaoyu, et al.
Publicado: (2021)

Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway
por: Meng, Xiangrui, et al.
Publicado: (2020)

Relationship Between Thyroid Autoantibodies and Recurrence of Papillary Thyroid Carcinoma in Children and Adolescents
por: Huang, Dongmei, et al.
Publicado: (2022)

LDHA induces EMT gene transcription and regulates autophagy to promote the metastasis and tumorigenesis of papillary thyroid carcinoma
por: Hou, Xiukun, et al.
Publicado: (2021)

Aurora kinase a promotes the progression of papillary thyroid carcinoma by activating the mTORC2-AKT signalling pathway
por: Zhao, Zewei, et al.
Publicado: (2022)

Risk factors for cervical lymph node metastasis in papillary thyroid microcarcinoma: a study of 1,587 patients
por: Zheng, Xiangqian, et al.
Publicado: (2019)

KDM1A promotes thyroid cancer progression and maintains stemness through the Wnt/β-catenin signaling pathway
por: Zhang, Wei, et al.
Publicado: (2022)

Isocitrate dehydrogenase gene variants in cancer and their clinical significance
por: Cadoux-Hudson, Thomas, et al.
Publicado: (2021)

To Explore the Inhibitory Mechanism of Quercetin in Thyroid Papillary Carcinoma through Network Pharmacology and Experiments
por: Sun, Ying, et al.
Publicado: (2022)

Immune gene signature delineates a subclass of thyroid cancer with unfavorable clinical outcomes
por: Zhi, Jingtai, et al.
Publicado: (2020)

Surgery and Radioactive Iodine Therapeutic Strategy for Patients Greater Than 60 Years of Age with Differentiated Thyroid Cancer
por: Tang, Tao, et al.
Publicado: (2022)

Comprehensive analysis of PPPCs family reveals the clinical significance of PPP1CA and PPP4C in breast cancer
por: Xie, Wenjun, et al.
Publicado: (2021)

Impact of major different variants of papillary thyroid microcarcinoma on the clinicopathological characteristics: the study of 1041 cases
por: Zhi, Jingtai, et al.
Publicado: (2017)

Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer
por: Zhang, Jun, et al.
Publicado: (2021)

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
por: OHBA, Shigeo, et al.
Publicado: (2016)

Mutation of Isocitrate Dehydrogenase 1 in Cholangiocarcinoma Impairs Tumor Progression by Inhibiting Isocitrate Metabolism
por: Su, Li, et al.
Publicado: (2020)

FATS regulates polyamine biosynthesis by promoting ODC degradation in an ERβ-dependent manner in non-small-cell lung cancer
por: Qiu, Li, et al.
Publicado: (2020)

Isocitrate dehydrogenase mutations in myeloid malignancies
por: Medeiros, B C, et al.
Publicado: (2017)

Targeting Aurora-A inhibits tumor progression and sensitizes thyroid carcinoma to Sorafenib by decreasing PFKFB3-mediated glycolysis
por: Jingtai, Zhi, et al.
Publicado: (2023)

Radiomic model for predicting mutations in the isocitrate dehydrogenase gene in glioblastomas
por: Hsieh, Kevin Li-Chun, et al.
Publicado: (2017)

The prognostic significance of wild-type isocitrate dehydrogenase 2 (IDH2) in breast cancer
por: Aljohani, Abrar I., et al.
Publicado: (2019)

Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
por: Liu, Xiaoyan, et al.
Publicado: (2019)

The Role of Isocitrate Dehydrogenases in Direct Reprogramming to Cardiomyocytes
por: Ishida, Tomoaki, et al.
Publicado: (2021)

Isocitrate Dehydrogenase (IDH)1/2 Mutations as Prognostic Markers in Patients With Glioblastomas
por: Chen, Jun-Rui, et al.
Publicado: (2016)

Characterization of the Isocitrate Dehydrogenase Gene Family and Their Response to Drought Stress in Maize
por: Wei, Ningning, et al.
Publicado: (2023)

Wild-Type Isocitrate Dehydrogenase-Dependent Oxidative Decarboxylation and Reductive Carboxylation in Cancer and Their Clinical Significance
por: He, Qiwei, et al.
Publicado: (2022)

Prognostic and diagnostic potential of isocitrate dehydrogenase 1 in esophageal squamous cell carcinoma
por: Chen, Xuan, et al.
Publicado: (2016)

Adult isocitrate dehydrogenase–mutant brainstem glioma: illustrative case
por: Ye, Vincent C., et al.
Publicado: (2021)

Isocitrate dehydrogenase mutations: new opportunities for translational research
por: Keum, Young-Sam, et al.
Publicado: (2015)

Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
por: Al-Khallaf, Hamoud
Publicado: (2017)

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics
por: Golub, Danielle, et al.
Publicado: (2019)

Ivosidenib in Isocitrate Dehydrogenase 1–Mutated Advanced Glioma
por: Mellinghoff, Ingo K., et al.
Publicado: (2020)

Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
por: Alzial, Gabriel, et al.
Publicado: (2021)

Metabolic adaptations in cancers expressing isocitrate dehydrogenase mutations
por: Hvinden, Ingvild Comfort, et al.
Publicado: (2021)

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
por: Liu, Yang, et al.
Publicado: (2023)

Active surveillance as a management strategy for papillary thyroid microcarcinoma
por: Zhang, Huan, et al.
Publicado: (2020)

Identification of potential pathogenic candidates or diagnostic biomarkers in papillary thyroid carcinoma using expression and methylation profiles
por: Wei, Songfeng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_54ja7aeup746dpkac7hv6au8lp